fingolimod hydrochloride has been researched along with Cancer of the Thyroid in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Desai, D; Doroszko, M; Eriksson, JE; Kemppainen, K; Niemelä, E; Niemi, R; Özliseli, E; Rahman, NA; Rosenholm, JM; Sahlgren, C; Törnquist, K | 1 |
| Huang, Z; Jiang, Z; Li, L; Zou, X | 1 |
| Asghar, MY; Kalhori, V; Magnusson, M; Pulli, I; Törnquist, K | 1 |
| Furberg, CD; Moore, TJ | 1 |
4 other study(ies) available for fingolimod hydrochloride and Cancer of the Thyroid
| Article | Year |
|---|---|
Nanoparticles carrying fingolimod and methotrexate enables targeted induction of apoptosis and immobilization of invasive thyroid cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Drug Delivery Systems; Fingolimod Hydrochloride; Folate Receptors, GPI-Anchored; Humans; Methotrexate; Nanoparticles; Neoplasm Invasiveness; Silicon Dioxide; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Selenium nanoparticles coated with pH responsive silk fibroin complex for fingolimod release and enhanced targeting in thyroid cancer.
Topics: Animals; Antineoplastic Agents; BALB 3T3 Cells; Cell Line, Tumor; Delayed-Action Preparations; Female; Fibroins; Fingolimod Hydrochloride; Humans; Hydrogen-Ion Concentration; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; Rats; Selenium; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2021 |
FTY720 (Fingolimod) attenuates basal and sphingosine-1-phosphate-evoked thyroid cancer cell invasion.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Movement; Chick Embryo; Chorioallantoic Membrane; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Sphingosine; Thyroid Neoplasms | 2016 |
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
Topics: Anticoagulants; Antineoplastic Agents; Benzimidazoles; beta-Alanine; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Dabigatran; Drug Approval; Efficiency, Organizational; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Patient Safety; Piperidines; Propylene Glycols; Quinazolines; Risk; Sphingosine; Stroke; Thyroid Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2012 |